Reiterating its commitment to dermatology, Almirall SA has entered a deal with US-based Dermira Inc. for the investigational anti-IL-13 monoclonal antibody lebrikizumab. The family-controlled Spanish group gets an option to exclusively license European rights to develop and commercialize lebrikizumab to treat atopic dermatitis, for which Dermira gets an upfront option fee of $30m.
If Almirall exercises its option to obtain the license - following receipt of data from an ongoing Phase IIb lebrikizumab...








